Results 201 to 210 of about 122,500 (261)

Targeting Inflammation by Pioglitazone and its R-Enantiomer Mitigates Pathological Myocardial Remodeling in Murine Hypertrophic Cardiomyopathy. [PDF]

JACC Basic Transl Sci
Pfaller AT, Veneziano C, Murthi SR, Stöckl JB, Shashikadze B, Flenkenthaler F, Gorham J, Moretti A, Kitanovic A, Gearing LJ, Heinrich F, Durek P, Lehmann K, Mashreghi MF, Ewert P, Fröhlich T, Schmitt JP, Spielmann N, Hrabě de Angelis M, Schmid M, Toepfer CN, Latz E, Klingel K, Santamaria G, Seidman JG, Seidman CE, Wolf CM.   +26 more
europepmc   +1 more source

Mavacamten in Obstructive Hypertrophic Cardiomyopathy and C282Y Homozygous Hereditary Hemochromatosis: A First-in-Human Report. [PDF]

JACC Case Rep
Sam R, Ananthaneni A, Planek MI, Kogan A, Gordon R.   +4 more
europepmc   +1 more source

Australian Guideline for the Identification and Management of Hypertension in Children and Adolescents

Journal of Paediatrics and Child Health, EarlyView.
N. G. Larkins, T. Medley, A. Black, K. A. Bolton, S. Chaturvedi, M. Clark, G. M. Gabb, J. P. Glenning, C. Grimes, R. C. Huang, A. Hyland, C. Jeffries‐Stokes, L. Kalman, S. Kaul, S. Kim, S. McTaggart, R. Kowalski, S. X. Li, S. McNab, D. Metz, A. S. Mihailidou, J. Monin, M. Nelson, M. Pathak, D. Roebuck, M. P. Schlaich, R. Sleaby, C. Quinlan, J. P. Mynard   +28 more
wiley   +1 more source

Heart rate and left ventricular remodeling after repaired coarctation of the aorta: a cross-sectional study.

Clin Hypertens
Vaccari M, Maldonado LE, Moros CG, Sardella A, Romo M, Romero CA, ARECO Study Group.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Left ventricular hypertrophy in hypertension

American Heart Journal, 1991
Major advances in left ventricular hypertrophy (LVH) and hypertension have occurred in recent years. The ability to diagnose LVH has been improved by echocardiography, and with this technique it has been shown that evidence of LVH is an important independent risk factor for cardiovascular disease.
F G, Dunn, J M, Burns, R S, Hornung
openaire   +2 more sources

Hypertension and Left-Ventricular Hypertrophy

Cardiology Clinics, 1995
Left-ventricular hypertrophy (LVH), the primary cardiac manifestation of hypertension, has been identified as the most powerful risk factor for future cardiovascular events causing morbidity and mortality, such as myocardial infarction, congestive heart failure, sudden death, and so forth.
F H, Messerli, F C, Aepfelbacher
openaire   +2 more sources

Left Ventricular Hypertrophy in Athletes

The American Journal of Cardiology, 1997
Left ventricular wall thickness >1.3 cm, septal-to-posterior wall ratios > 1.5, diastolic left ventricular size >6.0 cm, and eccentric or concentric remodeling are rare in athletes. Values outside of these cutoffs in an athlete of any age probably represent a pathologic state.
P S, Douglas, M L, O'Toole, S E, Katz, G S, Ginsburg, W D, Hiller, R H, Laird   +5 more
openaire   +2 more sources